{"id":60540,"date":"2026-03-23T14:41:33","date_gmt":"2026-03-23T06:41:33","guid":{"rendered":"https:\/\/flcube.com\/?p=60540"},"modified":"2026-03-23T14:41:34","modified_gmt":"2026-03-23T06:41:34","slug":"haihe-biopharma-wins-japan-approval-for-risovalisib-first-pi3k%ce%b1-inhibitor-for-ovarian-clear-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60540","title":{"rendered":"Haihe Biopharma Wins Japan Approval for Risovalisib \u2013 First PI3K\u03b1 Inhibitor for Ovarian Clear Cell Carcinoma"},"content":{"rendered":"\n

Haihe Biopharma Co., Ltd.<\/strong> announced that its independently developed selective PI3K\u03b1 inhibitor, Risovalisib Mesylate Tablets<\/strong>, has received marketing approval in Japan<\/strong> for Ovarian Clear Cell Carcinoma (OCCC) harboring PIK3CA mutations<\/strong> following chemotherapy progression \u2013 marking the world’s first monotherapy targeted treatment<\/strong> for this indication and the first selective PI3K\u03b1 inhibitor approved in Japan<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>Japan Ministry of Health, Labour and Welfare (MHLW) \/ PMDA<\/td><\/tr>
Product<\/strong><\/td>Risovalisib Mesylate Tablets<\/td><\/tr>
Company<\/strong><\/td>Haihe Biopharma Co., Ltd. (China\u2011based)<\/td><\/tr>
Drug Class<\/strong><\/td>Selective PI3K\u03b1 inhibitor<\/td><\/tr>
Indication<\/strong><\/td>PIK3CA\u2011mutated Ovarian Clear Cell Carcinoma (OCCC) post\u2011chemotherapy progression<\/td><\/tr>
Global Firsts<\/strong><\/td>First<\/strong> monotherapy targeted treatment for post\u2011chemo OCCC; First<\/strong> selective PI3K\u03b1 inhibitor in Japan<\/td><\/tr>
Chemical Structure<\/strong><\/td>Novel (proprietary to Haihe Biopharma)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Phase II Pivotal Trial (NCT05043922)<\/h2>\n\n\n\n
Study Design Element<\/th>Detail<\/th><\/tr><\/thead>
Trial Type<\/strong><\/td>Pivotal, single\u2011arm, open\u2011label, international multi\u2011center Phase II<\/td><\/tr>
Sites<\/strong><\/td>39 centers<\/strong> (China + Japan)<\/td><\/tr>
Patient Population<\/strong><\/td>OCCC with PIK3CA mutations<\/strong>; disease progressed after chemotherapy<\/td><\/tr>
Primary Endpoint<\/strong><\/td>Objective Response Rate (ORR)<\/strong> \u2013 BIRC\u2011assessed (Blinded Independent Radiology Committee)<\/td><\/tr>
Enrollment<\/strong><\/td>84 efficacy\u2011evaluable patients<\/strong><\/td><\/tr>
Geographic Distribution<\/strong><\/td>45.2% China \/ 54.8% Japan<\/td><\/tr>
Dosing<\/strong><\/td>40 mg orally once daily<\/strong>, fasting conditions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Efficacy & Safety Results<\/h3>\n\n\n\n
Endpoint<\/th>Result<\/th>Clinical Significance<\/th><\/tr><\/thead>
Anti\u2011tumor Activity<\/strong><\/td>Clinically meaningful<\/strong><\/td>Demonstrated efficacy in hard\u2011to\u2011treat OCCC population<\/td><\/tr>
Safety Profile<\/strong><\/td>Controllable and well\u2011tolerated<\/strong><\/td>Supports outpatient oral administration<\/td><\/tr>
Common AEs<\/strong><\/td>Hyperglycemia, skin rash<\/td>Consistent with PI3K\u03b1 inhibitor class; manageable with symptomatic treatment or dose adjustment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Dimension<\/th>Ovarian Clear Cell Carcinoma Landscape<\/th>Risovalisib Position<\/th><\/tr><\/thead>
Disease Biology<\/strong><\/td>OCCC accounts for ~10% of epithelial ovarian cancers; higher prevalence in Asia; PIK3CA mutations in ~30\u201140%<\/td>First targeted therapy addressing PIK3CA\u2011driven OCCC subtype<\/td><\/tr>
Standard of Care<\/strong><\/td>Platinum\u2011based chemotherapy; high recurrence rate; limited effective options post\u2011progression<\/td>First approved monotherapy for post\u2011chemo progression \u2013 fills critical gap<\/td><\/tr>
Competitive Pipeline<\/strong><\/td>PARP inhibitors (limited efficacy in OCCC vs. high\u2011grade serous); immunotherapy trials ongoing<\/td>PI3K\u03b1 mechanism distinct from DNA repair\/immune approaches; potential for combination strategies<\/td><\/tr>
Geographic Strategy<\/strong><\/td>Japan approval leverages Asian patient data (54.8% of trial); China NDA submission anticipated<\/td>“Japan\u2011first” regulatory strategy may accelerate China approval via mutual recognition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n